Drugs / CIC Vaccine with Matrix-M Adjuvant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05519839 | Dec 2022 → Jul 2023 | COVID-19, influenza | Novavax | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIC Vaccine with Matrix-M Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05519839 ↗ |
| Modality | Vaccine | “CIC Vaccine with Matrix-M Adjuvant” NCT05519839 ↗ |
| Route | Intramuscular | “Intramuscular (deltoid) injections” NCT05519839 ↗ |